OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · IEX Real-Time Price · USD
2.20
0.00 (0.00%)
Jul 5, 2022 3:59 PM EDT - Market closed

Company Description

OKYO Pharma is a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.

Our research program is focused on a novel G Protein-Coupled Receptor, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need.

Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye disease.

We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue candidate that is currently in developmental stage.

OKYO Pharma Limited
Country United Kingdom
Founded 2007
IPO Date May 17, 2022
Industry Biotechnology
Sector Health Care
Employees 6
CEO Dr. Gary S. Jacob

Contact Details

Address:
Martello Court, Admiral Park
St. Peter Port GY1 3HB
Guernsey
Phone 44 20 7495 2379
Website okyopharma.com

Stock Details

Ticker Symbol OKYO
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency US Dollars
IPO Price $4.00
CIK Code 1849296
ISIN Number US6793451088

Key Executives

Name Position
Dr. Gary S. Jacob Ph.D. Chief Executive Officer and Executive Director
Michael Paul Beck Founder
Keeren Shah Chief Financial Officer
Dr. Rajkumar Patil Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Jun 9, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 20, 2022 4 Statement of changes in beneficial ownership of securities
May 20, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 19, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 19, 2022 4 Statement of changes in beneficial ownership of securities
May 19, 2022 4 Statement of changes in beneficial ownership of securities
May 18, 2022 4/A Statement of changes in beneficial ownership of securities
May 18, 2022 4 Statement of changes in beneficial ownership of securities
May 18, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 18, 2022 424B4 Prospectus [Rule 424(b)(4)]